David Shaw’s Esperion Therapeutics ESPR Stock Holding History

David Shaw’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-20,000	Closed	-$520K	–	4165
2020 Q4	$520K	Hold	20,000	–	–	﹤0.01%	3368
2020 Q3	$743K	Hold	20,000	–	–	﹤0.01%	3036
2020 Q2	$1.03M	Hold	20,000	–	–	﹤0.01%	2910
2020 Q1	$631K	Sell	20,000 -9,000	-31%	-$475K	﹤0.01%	3076
2019 Q4	$1.73M	Hold	29,000	–	–	﹤0.01%	2589
2019 Q3	$1.06M	Hold	29,000	–	–	﹤0.01%	2790
2019 Q2	$1.35M	Sell	29,000 -100	-0.3%	-$4.7K	﹤0.01%	2499
2019 Q1	$1.17M	Buy	29,100 +100	+0.3%	+$4.49K	﹤0.01%	2512
2018 Q4	$1.33M	Buy	29,000 +10,000	+53%	+$482K	﹤0.01%	2460
2018 Q3	$843K	Sell	19,000 -41,200	-68%	-$1.89M	﹤0.01%	2789
2018 Q2	$2.36M	Buy	+60,200	New	+$3.04M	﹤0.01%	2107
2015 Q4	–	Sell	-10,000	Closed	-$236K	–	3847
2015 Q3	$236K	Hold	10,000	–	–	﹤0.01%	3433
2015 Q2	$818K	Buy	+10,000	New	+$979K	﹤0.01%	2843

Other funds holding ESPR

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

David Shaw's ESPR Position: Q2 2026 in Review

David Shaw sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 6,540,785 shares — an estimated $17.9M sold.

David Shaw first reported a position in ESPR in Q1 2015 and held it in 24 quarters. The position peaked at $25.5M in Q4 2025. 189 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

David Shaw reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
David Shaw sold 6,540,785 Esperion Therapeutics shares in Q2 2026, an estimated $17.9M.
David Shaw first reported a position in Esperion Therapeutics in Q1 2015 and held it in 24 quarters.
David Shaw's Esperion Therapeutics position peaked at $25.5M in Q4 2025.
189 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.